Endometriosis: New Insights and Opportunities for Relief of Symptoms

This is a comprehensive narrative review from two leading endometriosis researchers at the University of Edinburgh. It covers the full landscape of where the science stands — from what causes the disease, to why diagnosis takes so long, to what’s actually in the treatment pipeline. If you want one paper that maps the current state of endometriosis research, this is it.

The authors frame endometriosis as a chronic neuroinflammatory disorder — not a reproductive inconvenience. That language matters. It positions the disease alongside other serious inflammatory conditions and shifts the conversation away from “bad periods” toward the multi-system reality patients actually live with.

The review documents what patients already know: endometriosis causes far more than pelvic pain. Fatigue, GI symptoms, bloating, urinary issues, and mood disorders are all part of the disease profile. People with endo have a twofold increased risk of IBS and significantly elevated odds of psychiatric conditions — independent of pain severity, socioeconomic status, and BMI. These aren’t side effects of being stressed about your diagnosis. They’re part of the biology.

The paper also breaks down three distinct types of pain operating in endometriosis: nociceptive pain (tissue damage from lesions), neuropathic pain (nerve damage), and nociplastic pain — where the nervous system itself becomes rewired to amplify pain signals even in the absence of new damage. This is why some patients continue to experience severe pain even after successful surgery. The nervous system has learned pain as its default.

Laparoscopic surgery remains the gold standard for definitive diagnosis. Imaging has improved — ultrasound and MRI can now detect ovarian endometriomas and deep lesions — but superficial peritoneal disease, which accounts for the majority of cases, remains largely invisible to current imaging.

Biomarker research is underway, including microRNA panels in serum and saliva and fecal metabolite candidates, but none has been validated at scale. AI-assisted imaging analysis is also in early development. Until a reliable non-invasive test exists, patients will continue to navigate a diagnostic system that requires them to prove the severity of a disease the system can’t easily see.

Endometriosis lesions are not just displaced tissue sitting passively outside the uterus. They are active microenvironments with their own steroid production, immune cell populations, and blood and nerve supply. The review describes neuro-angiogenesis — the simultaneous growth of new blood vessels and nerve fibers into lesions — as a key feature of disease progression. Lesions essentially build their own infrastructure.

Recent single-cell analysis has revealed metabolic dysfunction within these lesions, specifically altered glycolytic and oxidative metabolism in perivascular and stromal cells. Macrophages — immune cells that should be clearing the debris — are present but behaving abnormally, contributing to the inflammatory environment rather than resolving it.

Large-scale genomic studies have now identified 42 genetic loci associated with endometriosis, and many of these overlap with migraine, chronic pain, asthma, inflammatory bowel disease, depression, and other GI disorders. One specific locus — DGKB rs12666606 — directly links endometriosis and depression at the genetic level.

This is not a coincidence, and it’s not “all in your head.” If you have endo and also live with migraines, brain fog, gut issues, and mood disorders, the genetic data says those conditions share biological roots with your endometriosis. This also means drugs developed for those other conditions may work for endo — drug repurposing is one of the fastest paths to new treatments.

The paper is honest about the state of treatment. Analgesics have limited long-term use. Surgery has recurrence rates of 40–50% within five years. Hormonal suppressants cause menopause-like side effects and prevent pregnancy during use — a cruel trade-off for a disease that already threatens fertility. Patient dissatisfaction with current options is well-documented.

30–50% of endometriosis patients experience difficulty conceiving, and the disease is associated with increased risks of miscarriage, ectopic pregnancy, placenta previa, and preterm birth. The review emphasizes that fertility conversations need to happen earlier — not as an afterthought when patients are already struggling.

Several new drug candidates are in Phase 2 and 3 clinical trials, and they represent a genuine departure from the hormone-suppression playbook:

• Gefapixant, a P2X3 receptor antagonist, targets pain signaling directly rather than suppressing hormones
• MT-2990, an IL-33 inhibitor, goes after inflammatory pathways specific to endo lesions
• Cabergoline, a dopamine agonist, is being tested against standard hormonal therapy
• Aromatase inhibitors as monotherapy for lesion-specific estrogen production

The review also emphasizes drug repurposing — adapting medications that already work for conditions sharing genetic pathways with endometriosis. This is one of the most efficient routes to expanding treatment options.

One of the most important threads in this paper is its explicit endorsement of non-medical and self-management strategies — including nutrition — as legitimate components of care. This is not wellness fluff. The authors argue that personalized endometriosis care requires multidisciplinary teams that include dieticians, physiotherapists, and mental health experts alongside surgeons and physicians.

The paper also highlights self-compassion as a protective factor and interoceptive awareness — the ability to perceive and interpret your own body’s signals — as meaningfully connected to depressive symptom severity. Learning to listen to your body isn’t soft advice. It’s clinically relevant.